Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1
Authors:
Open Access
- 26 June 2023
- journal article
- research article
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 33, 227-239
Abstract
No abstract availableKeywords
Funding Information
- American Cancer Society
- Gilbert Family Foundation
This publication has 39 references indexed in Scilit:
- Attenuation of Nonsense-Mediated mRNA Decay Enhances In Vivo Nonsense SuppressionPLOS ONE, 2013
- Suppression of nonsense mutations as a therapeutic approach to treat genetic diseasesWIREs RNA, 2011
- Gentamicin‐induced readthrough of stop codons in duchenne muscular dystrophyAnnals of Neurology, 2010
- V600E BRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathwayProceedings of the National Academy of Sciences, 2009
- PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR -G542X nonsense allele in a CF mouse modelProceedings of the National Academy of Sciences, 2008
- PTC124 targets genetic disorders caused by nonsense mutationsNature, 2007
- In vitroprediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot studyBMC Medicine, 2007
- Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicinJournal of Clinical Investigation, 2007
- A module of negative feedback regulators defines growth factor signalingNature Genetics, 2007
- A nonsense mutation at Arg-1947 in the NF1 gene in a case of neurofibromatosis type 1 in a Korean patientJournal of Human Genetics, 2000